TICKERNOMICS Sign up
Last Update: 2024-03-28 02:09:13
BIOGEN INC. ( BIIB ) https://www.biogen.com
212.02USD
Sector:
Healthcare
Industry:
Drug Manufacturers-General
Country:
United States
1y
3y
5y
10y
Historical Returns*:
SPY
31.15%
-21.55%
BIIB
SPY
32.74%
-23.36%
BIIB
SPY
92.93%
-10.31%
BIIB
SPY
224.41%
-21.74%
BIIB
*Assumes dividends reinvested
Market Stats:
Market Capitalization($MM)
Enterprise Value($MM)
Daily Volume(MM)
31986.68
35314.38
1.49
Valuation Metrics:
Price/Earnings Ratio
Price/Sales Ratio
Price/Book Value
FCF Yield(%)
Dividend Yield(%)
EV/EBITDA
21.88
3.20
2.16
4.82
0.00
29.75
Profitability Stats:
Operating Margin %(ttm)
Gross Profit %(ttm)
EBITDA Margin %(ttm)
-5.58
73.93
11.90
Shareholder Value Creation:
Cost of Capital %(est)
ROIC %(ttm)
ROCE %(ttm)
Beta
5.1652
-0.60
-2.53
0.24
Other Earnings and Cash Flow Stats:
BIOGEN INC. ( BIIB ) Net Income TTM ($MM) is 2004.90
BIOGEN INC. ( BIIB ) Operating Income TTM ($MM) is 1576.10
BIOGEN INC. ( BIIB ) Owners' Earnings Annual ($MM) is 1807.26
BIOGEN INC. ( BIIB ) Current Price to Owners' Earnings ratio is 17.00
BIOGEN INC. ( BIIB ) EBITDA TTM ($MM) is 1982.30
BIOGEN INC. ( BIIB ) EBITDA Margin is 11.90%
Capital Allocation:
BIOGEN INC. ( BIIB ) has paid 0.00 dividends per share and bought back 1.1 million shares in the past 12 months
BIOGEN INC. ( BIIB ) has reduced its debt by 6439.8 million USD in the last 12 months
Capital Structure:
BIOGEN INC. ( BIIB ) Interest-bearing Debt ($MM) as of last quarter is 6788
BIOGEN INC. ( BIIB ) Annual Working Capital Investments ($MM) are 4341
BIOGEN INC. ( BIIB ) Book Value ($MM) as of last quarter is 14799
BIOGEN INC. ( BIIB ) Debt/Capital as of last quarter is 45%
Other Balance Sheet Stats:
BIOGEN INC. ( BIIB ) has 2287 million in cash on hand as of last quarter
BIOGEN INC. ( BIIB ) has 3434 million of liabilities due within 12 months, and long term debt 7286 as of last quarter
BIOGEN INC. ( BIIB ) has 144 common shares outstanding as of last quarter
BIOGEN INC. ( BIIB ) has 0 million USD of preferred stock value
Academic Scores:
BIOGEN INC. ( BIIB ) Altman Z-Score is 3.15 as of last quarter
BIOGEN INC. ( BIIB ) Piotroski Score is 6.00 as of last quarter
Corporate Governance:
BIOGEN INC. ( BIIB ) largest shareholder is PRIMECAP Management Company owning 16264481 shares at 3448.40 ($MM) value
Priya Singhal(an insider) Sold 262 shares of BIOGEN INC. ( BIIB ) for the amount of $57962.26 on 2024-02-22
0.68% of BIOGEN INC. ( BIIB ) is held by insiders, and 90.87% is held by institutions
BIOGEN INC. ( BIIB ) went public on 1991-09-16
Other BIOGEN INC. ( BIIB ) financial metrics:
FCF:1228.00
Unlevered Free Cash Flow:-3036.00
EPS:-1.88
Operating Margin:-5.58
Gross Profit Margin:73.93
Div. Payout Ratio%:0.00
Div. Growth YoY%:0.00
Equity Return%:-1.84
Beta:0.24
Buffet's Owners Earnings:1807.26
Price to Owner's Earnings:17.00
About BIOGEN INC. ( BIIB ) :
Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases in the United States, Europe, Germany, Asia, and internationally. The company offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; ADUHELM to treat Alzheimer's disease; FUMADERM to treat plaque psoriasis; BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; FLIXABI, an infliximab biosimilar referencing REMICADE; and BYOOVIZ, a ranibizumab biosimilar referencing LUCENTIS. It also provides RITUXAN for treating non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), rheumatoid arthritis, two forms of ANCA-associated vasculitis, and pemphigus vulgaris; RITUXAN HYCELA for non-Hodgkin's lymphoma and CLL; GAZYVA to treat CLL and follicular lymphoma; OCREVUS for relapsing MS and primary progressive MS; LUNSUMIO to treat relapsed or refractory follicular lymphoma; glofitamab for non-Hodgkin's lymphoma; and other anti-CD20 therapies. In addition, the company is developing various products for the treatment of MS, Alzheimer's disease and dementia, neuromuscular disorders, Parkinson's disease and movement disorders, neuropsychiatry, immunology related diseases, neurovascular disorders, genetic neurodevelopmental disorders, and biosimilars, which are under various stages of development. Biogen Inc. has collaboration and license agreements with Acorda Therapeutics, Inc.; Alkermes Pharma Ireland Limited; Denali Therapeutics Inc.; Eisai Co., Ltd.; Genentech, Inc.; Neurimmune SubOne AG; Ionis Pharmaceuticals, Inc.; Samsung Bioepis Co., Ltd.; Sangamo Therapeutics, Inc.; and Sage Therapeutics, Inc. The company was founded in 1978 and is headquartered in Cambridge, Massachusetts.
User Content from Tickernomics. Created by Luminus.
DISCLAIMER

This web site and its creators are not certified financial advisors. All opinions/suggestions expressed on this website should not be treated as specific inducement to make a particular investment or follow a particular strategy, but only as an expression of an opinion.The Company doesn't warrant the information provided on the website for its completeness or accuracy, and it should not be relied upon as such. The Company is not under any obligation to update or correct any information provided on this website.The content of this website is published in the United States of America and persons who access it agree to do so in accordance with applicable U.S. law.Past performance is not indicative of future results. The Company doesn't guarantee any specific outcome or profit. You should be aware of the real risk of loss in following any strategy or investment discussed on this website.Strategies or investments discussed may fluctuate in price or value. Investors may get back less than invested. Investments or strategies mentioned on this website may not be suitable for you. This material does not take into account your particular investment objectives,financial situation or needs and is not intended as recommendations appropriate for you. You must make an independent decision regarding investments or strategies mentioned on this website. Before acting on information on this website, you should consider whether it is suitable for your particular circumstances and strongly consider seeking advice from your own financial or investment adviser.